VEA
ELVN icon

Virtus ETF Advisers’s Enliven Therapeutics ELVN Stock Holding History

Virtus ETF Advisers’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-3,091
Closed -$69.5K – 539
2024
Q4 		$69.5K Sell
3,091
-1,097
-26% -$28.4K 0.03% 380
2024
Q3 		$107K Buy
4,188
+77
+2% +$1.78K 0.05% 367
2024
Q2 		$96.1K Buy
+4,111
New +$86.5K 0.05% 335

Other funds holding ELVN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

Virtus ETF Advisers's ELVN Position: Q1 2025 in Review

Virtus ETF Advisers sold out of Enliven Therapeutics (ELVN) in Q1 2025, closing a stake of 3,091 shares — an estimated $69.5K sold.

Virtus ETF Advisers first reported a position in ELVN in Q2 2024 and held it in 3 quarters. The position peaked at $107K in Q3 2024. 121 funds tracked by Wall St. Rank hold ELVN as of Q1 2025.

  • Virtus ETF Advisers reported no remaining Enliven Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Virtus ETF Advisers sold 3,091 Enliven Therapeutics shares in Q1 2025, an estimated $69.5K.
  • Virtus ETF Advisers first reported a position in Enliven Therapeutics in Q2 2024 and held it in 3 quarters.
  • Virtus ETF Advisers's Enliven Therapeutics position peaked at $107K in Q3 2024.
  • 121 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q1 2025.

Based on Virtus ETF Advisers's 13F filing for Q1 2025, filed 14 May 2025.